Multimeric form of human rhinovirus receptor protein
AssigneeBayer Aktiengesellschaft
InventorsJeffrey M. Greve, Alan McClelland
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel forms and configurations of intercellular adhesion molecule (ICAM) including multimeric configurations that effectively bind to human rhinovirus and can effectively reduce HRV infectivity. When in a multimeric configuration, preferably as dimers, these proteins display enhanced binding of HRV and are able to reduce HRV infectivity as well as the infectivity of other viruses known to bind to the "major" group human rhinovirus receptor (HRR). The multimerized proteins may also be used to block tICAM interaction with lymphocyte function-associated antigen-1 (LFA-1).
Claims3
A dimeric antiviral agent comprising an antibody selected from the group consisting of CL 203 and antibodies which bind to the same epitope as CL203, said antibody being bound to two monomers wherein said monomers may be the same or different and are each independently selected from the group consisting of truncated forms of intercellular adhesions molecule-1 (tICAMs).
Dependencies are inferred from the claim text.